References: Aminoglycoside use in special patient groups
Boyd SE, Charani E, Lyons T, Frost G, Holmes AH. Information provision for antibacterial dosing in the obese patient: a sizeable absence? J Antimicrob Chemother 2016;71(12):3588-92. https://www.ncbi.nlm.nih.gov/pubmed/27538956
Chean R, Garland SM, Leung L. Gentamicin in pregnancy: seeing past the drug categorisation in pregnancy. Intern Med J 2017;47(1):124-5. https://www.ncbi.nlm.nih.gov/pubmed/28076911
Mahmoud SH, Shen C. Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing. Pharmaceutics 2017;9(3). https://www.ncbi.nlm.nih.gov/pubmed/28926966
Llanos-Paez CC, Staatz CE, Lawson R, Hennig S. A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing. Antimicrob Agents Chemother 2017;61(8). https://www.ncbi.nlm.nih.gov/pubmed/28533244
Martingano D, Guan X, Renson A, Singh S, Kesavan Nasir M, Kim J, et al. Daily dosing of gentamicin using ideal body weight for the treatment of intrapartum chorioamnionitis: a pilot study. J Matern Fetal Neonatal Med 2018;31(9):1194-7. https://www.ncbi.nlm.nih.gov/pubmed/28349720
Moffett BS, Kam C, Galati M, Schmees L, Stitt GA, Revell PA, et al. The "Ideal" Body Weight for Pediatric Gentamicin Dosing in the Era of Obesity: A Population Pharmacokinetic Analysis. Ther Drug Monit 2018;40(3):322-9. https://www.ncbi.nlm.nih.gov/pubmed/29521784
Smit C, Wasmann RE, Goulooze SC, Hazebroek EJ, Van Dongen EPA, Burgers DMT, et al. A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. Clin Pharmacokinet 2019;58(10):1333-43. https://www.ncbi.nlm.nih.gov/pubmed/31016671
The Royal Women’s Hospital. Gentamicin. Pregnancy and Breastfeeding Medicines Guide. 2023 ed. Victoria, Australia: The Royal Women’s Hospital; 2023. https://thewomenspbmg.org.au/medicines/gentamicin
